Opinion|Videos|September 23, 2024
Contemporary Guidelines for CRM Conditions
Key Takeaways
- Professional organizations have developed guidelines to manage the interconnectivity of CRM conditions, reflecting advancements in understanding cardiovascular, renal, and metabolic health.
- Recent updates in guidelines include the integration of novel therapeutic agents and personalized treatment strategies, enhancing evidence-based practices.
Key opinion leaders review current guidelines for cardiometabolic conditions, emphasizing recent advancements in the field.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How do guidelines from professional organizations, including ACC, AHA, ADA, KDIGO, ACE, and DCRMi, address the management and interconnectivity of CRM conditions?
- How have these guidelines evolved in recent years? What are the notable guideline updates in recent years?
- What impact have these guidelines had on the treatment outcomes of patients with CRM conditions?
- What gaps are there in these guidelines regarding the management of CRM conditions?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article
Imlunestrant plus abemaciclib doubled median PFS in patients with ESR1-mutated advanced breast cancer.
Rebisufligene etisparvovec-hopf (Fayuvi; Ultragenyx) is a 1-time gene therapy that addresses the underlying cause of Sanfilippo syndrome type A.
Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
Karen van Caulil, PhD, on how employers can improve cancer care by investing in access, prevention, and support through treatment and survivorship.
The study’s primary end point of event-free survival demonstrated a 49% reduction in mortality risk between the blinatumomab and control cohorts.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
AI-assisted spirometry, imaging biomarkers, and population screening strategies highlighted early detection and prevention as a throughline at the ERS Congress.
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Imlunestrant Plus Abemaciclib for Breast Cancer
2
FDA Approves First Treatment for Sanfilippo Syndrome Type A
3
Higher CPAP Adherence Linked With Lower Mortality Risk in OSA
4
World Alzheimer Day: Young-Onset Alzheimer Disease Often Misdiagnosed
5